Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05918809 · ClinicalTrials.gov registry record
Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings
A clinical trial of Diffuse Large B Cell Lymphoma, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 1,031
- Enrollment target
- 1
- Study location
NCT05918809 is a study of Diffuse Large B Cell Lymphoma that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,031 participants, above the 210-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (391% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05918809, a study of Diffuse Large B Cell Lymphoma, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 1,031 participants
- Enrollment target
- 1
- Study location
Study Summary
A retrospective, non-interventional cohort study was used to address the study objectives. This study aimed to provide a better understanding of real-world healthcare resource utilization (HRU) and healthcare reimbursement costs associated with chimeric antigen receptor modified T cell (CAR-T) therapy among patients with DLBCL.
Conditions Studied
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,031 participants |
| Start Date | 2021-07-25 |
| Est. Completion | 2022-06-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05918809
The ClinicalTrials.gov registry entry for NCT05918809 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,031 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 210-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (391% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 0 interventions.
NCT05918809 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT05918809 about?
NCT05918809 is a clinical study titled "Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings". A retrospective, non-interventional cohort study was used to address the study objectives. This study aimed to provide a better understanding of real-world healthcare resource utilization (HRU) and healthcare reimbursement costs associated with chimeric antigen receptor modified T cell (CAR-T) thera...
What is the current status of trial NCT05918809?
This trial is currently completed. The enrollment target is 1,031 participants. The study started on 2021-07-25. Estimated completion is 2022-06-17.
What conditions does trial NCT05918809 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.
Who is sponsoring clinical trial NCT05918809?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05918809 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology
RECRUITING
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
RECRUITING · Phase 2
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.